Thorne HealthTech (NASDAQ:THRN – Get Rating) issued an update on its FY 2022 earnings guidance on Wednesday morning. The company provided earnings per share (EPS) guidance of $0.28-$0.30 for the period, compared to the consensus estimate of $0.31. The company issued revenue guidance of $240.00 million-$250.00 million, compared to the consensus revenue estimate of $249.14 million.
NASDAQ THRN traded up $0.52 on Thursday, hitting $6.78. 881 shares of the company’s stock traded hands, compared to its average volume of 94,228. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.34 and a current ratio of 3.93. Thorne HealthTech has a 1-year low of $4.17 and a 1-year high of $10.13. The firm’s 50-day moving average price is $6.15 and its two-hundred day moving average price is $6.46.
Thorne HealthTech (NASDAQ:THRN – Get Rating) last announced its quarterly earnings data on Monday, March 14th. The company reported $0.03 EPS for the quarter, missing the consensus estimate of $0.09 by ($0.06). The business had revenue of $49.86 million for the quarter. As a group, analysts predict that Thorne HealthTech will post 0.32 earnings per share for the current year.
In other news, Director Saloni S. Varma bought 9,223 shares of the firm’s stock in a transaction that occurred on Wednesday, March 23rd. The stock was purchased at an average cost of $6.01 per share, for a total transaction of $55,430.23. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website.
A number of hedge funds and other institutional investors have recently modified their holdings of THRN. Deutsche Bank AG purchased a new stake in Thorne HealthTech in the 4th quarter worth $25,000. Wells Fargo & Company MN purchased a new stake in shares of Thorne HealthTech during the fourth quarter worth $26,000. Nuveen Asset Management LLC acquired a new stake in shares of Thorne HealthTech in the fourth quarter valued at about $65,000. JPMorgan Chase & Co. lifted its stake in shares of Thorne HealthTech by 261.5% in the first quarter. JPMorgan Chase & Co. now owns 13,116 shares of the company’s stock worth $83,000 after buying an additional 9,488 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. purchased a new position in shares of Thorne HealthTech in the fourth quarter worth about $91,000. 24.92% of the stock is owned by institutional investors.
Thorne HealthTech Company Profile (Get Rating)
Thorne HealthTech, Inc, a science-driven wellness company, provides solutions and personalized approaches to health and wellness in the United States and internationally. It offers various health tests, such as sleep, stress, weight management, gut health, heavy metals, biological age, and other health tests that generate molecular portraits for its customers, as well as develops nutritional supplements and offers wellness education solutions.
- Get a free copy of the StockNews.com research report on Thorne HealthTech (THRN)
- Dutch Bros Gets Scalded By Inflation
- The S&P 500 Could Fall Another 28%
- Corning Stock is a Technology Value Play
- Wolverine Worldwide Is Ready To Rebound
- Anheuser-Busch InBev May Need One More Quarter to Confirm a Buy Signal
Receive News & Ratings for Thorne HealthTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thorne HealthTech and related companies with MarketBeat.com's FREE daily email newsletter.